Pub Date : 2016-11-01DOI: 10.1080/23809000.2016.1230018
G. Armento, L. Stumbo, G. Mazzara, A. Zoccoli, G. Tonini
AbstractCancer patient can present a set of physical problems, psychosocial and spiritual needs that require additional and specific treatments. The critical factor that presents itself is the planning of an appropriate program of care and treatment defined “Simultaneous Palliative Care”. The alleviation of suffering, perceived as a global experience of the whole person, is a central goal of palliative care; interventions that modulate the experiential dimension of suffering can enhance the relief of a cancer patient. A better integration of oncologists and supportive/palliative care specialists could help patients with severe distress to minimize the burden of progressive cancer. Considered in that light, a model of integrated medicine employed in a process of gradual treatment improvement, could represent the beginning of a new medical standard necessary because of the complexity of patients experiencing an advanced cancer.
{"title":"Simultaneous palliative care: from philosophy to practice","authors":"G. Armento, L. Stumbo, G. Mazzara, A. Zoccoli, G. Tonini","doi":"10.1080/23809000.2016.1230018","DOIUrl":"https://doi.org/10.1080/23809000.2016.1230018","url":null,"abstract":"AbstractCancer patient can present a set of physical problems, psychosocial and spiritual needs that require additional and specific treatments. The critical factor that presents itself is the planning of an appropriate program of care and treatment defined “Simultaneous Palliative Care”. The alleviation of suffering, perceived as a global experience of the whole person, is a central goal of palliative care; interventions that modulate the experiential dimension of suffering can enhance the relief of a cancer patient. A better integration of oncologists and supportive/palliative care specialists could help patients with severe distress to minimize the burden of progressive cancer. Considered in that light, a model of integrated medicine employed in a process of gradual treatment improvement, could represent the beginning of a new medical standard necessary because of the complexity of patients experiencing an advanced cancer.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"421 - 423"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1230018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-01DOI: 10.1080/23809000.2016.1255552
J. Sampson, K. Hamman
ABSTRACT Introduction: Genetic testing for hereditary cancer syndromes, including those with an increased risk for pancreatic cancer, has become more routine for patients and families with a personal and/or family history of cancer. Genetics professionals, including genetic counselors and medical geneticists, are specially trained to elicit and assess personal and family history, and to discuss appropriate genetic testing options and genetic test results with patients and families. Areas covered: The purpose of this article is to review hereditary cancer syndromes associated with an increased risk for pancreatic cancer, available genetic testing options, and pancreatic cancer screening modalities. Expert commentary: With recent advances in genetic testing methodologies, clinical and research genetic testing options, and the increased identification of somatic and germline variants in genes associated with hereditary cancer syndromes, the role of the genetic counselor in the multi-disciplinary oncology team is expanding and significant.
{"title":"A current picture of genetic counseling for familial pancreatic cancer","authors":"J. Sampson, K. Hamman","doi":"10.1080/23809000.2016.1255552","DOIUrl":"https://doi.org/10.1080/23809000.2016.1255552","url":null,"abstract":"ABSTRACT Introduction: Genetic testing for hereditary cancer syndromes, including those with an increased risk for pancreatic cancer, has become more routine for patients and families with a personal and/or family history of cancer. Genetics professionals, including genetic counselors and medical geneticists, are specially trained to elicit and assess personal and family history, and to discuss appropriate genetic testing options and genetic test results with patients and families. Areas covered: The purpose of this article is to review hereditary cancer syndromes associated with an increased risk for pancreatic cancer, available genetic testing options, and pancreatic cancer screening modalities. Expert commentary: With recent advances in genetic testing methodologies, clinical and research genetic testing options, and the increased identification of somatic and germline variants in genes associated with hereditary cancer syndromes, the role of the genetic counselor in the multi-disciplinary oncology team is expanding and significant.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"425 - 432"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1255552","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-10-14DOI: 10.1080/23809000.2016.1241660
S. Baker, A. Fairchild
ABSTRACT Introduction: Bone metastases are a frequent complication of advanced cancer, the most common cause of cancer-related pain and a source of significant morbidity and mortality. Optimal management can reduce skeletal-related events and improve quality of life. Areas covered: This article reviews the indications, treatment regimens and outcomes of palliative radiotherapy (RT) for symptomatic complicated and uncomplicated bone metastases, including pain, function and quality of life. Expert commentary: Patients with a limited number of bone metastases, termed ‘oligometastases’, may be candidates for a stereotactic ablative approach. For the majority, however, conventional external beam radiotherapy is the mainstay of non-invasive treatment. In concert with a multi-disciplinary management approach, RT reduces pain and improves function and quality of life.
{"title":"Palliative radiation in advanced cancer patients with symptomatic bone metastases","authors":"S. Baker, A. Fairchild","doi":"10.1080/23809000.2016.1241660","DOIUrl":"https://doi.org/10.1080/23809000.2016.1241660","url":null,"abstract":"ABSTRACT Introduction: Bone metastases are a frequent complication of advanced cancer, the most common cause of cancer-related pain and a source of significant morbidity and mortality. Optimal management can reduce skeletal-related events and improve quality of life. Areas covered: This article reviews the indications, treatment regimens and outcomes of palliative radiotherapy (RT) for symptomatic complicated and uncomplicated bone metastases, including pain, function and quality of life. Expert commentary: Patients with a limited number of bone metastases, termed ‘oligometastases’, may be candidates for a stereotactic ablative approach. For the majority, however, conventional external beam radiotherapy is the mainstay of non-invasive treatment. In concert with a multi-disciplinary management approach, RT reduces pain and improves function and quality of life.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"8 1","pages":"449 - 457"},"PeriodicalIF":0.0,"publicationDate":"2016-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1241660","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-02DOI: 10.1080/23809000.2016.1230019
J. Armer, J. Feldman, Pamela L. Ostby, K. M. Thrift, B. Lasinski, Marcia Beck, Julia R. Rodrick, S. Norton, Yuanlu Sun, T. Udmuangpia, Nathan C. Armer, B. Stewart
ABSTRACT Introduction: This expert review examines the evidence base for lymphedema management and recommends ways to improve outcomes for breast cancer survivors at risk of and living with lymphedema through simplifying evidence-based self-management recommendations. Lymphedema risk-reduction and self-management behaviors can be complex and burdensome to survivors, underscoring the need for simplifying the self-management recommendations. Areas covered: Systematic reviews on complete decongestive therapy; complementary/alternative therapies; botanicals; exercise; surgical treatment; intermittent pneumatic compression therapy; psychosocial issues; self-management; and economic and health policy are summarized. Historic perspectives and future projections are presented. Expert commentary: The reviews establish the evidence base for the recommendations for simplification of self-management guidelines for persons at risk for and living with breast cancer-related lymphedema. Further research is needed to enhance levels of evidence for breast cancer-related lymphedema management. More rigorously-designed studies with larger samples, longer follow-up, and finely-tuned interventions and dosages are needed to extend our evidence base.
{"title":"Simplifying evidence-based management of breast cancer-related lymphedema","authors":"J. Armer, J. Feldman, Pamela L. Ostby, K. M. Thrift, B. Lasinski, Marcia Beck, Julia R. Rodrick, S. Norton, Yuanlu Sun, T. Udmuangpia, Nathan C. Armer, B. Stewart","doi":"10.1080/23809000.2016.1230019","DOIUrl":"https://doi.org/10.1080/23809000.2016.1230019","url":null,"abstract":"ABSTRACT Introduction: This expert review examines the evidence base for lymphedema management and recommends ways to improve outcomes for breast cancer survivors at risk of and living with lymphedema through simplifying evidence-based self-management recommendations. Lymphedema risk-reduction and self-management behaviors can be complex and burdensome to survivors, underscoring the need for simplifying the self-management recommendations. Areas covered: Systematic reviews on complete decongestive therapy; complementary/alternative therapies; botanicals; exercise; surgical treatment; intermittent pneumatic compression therapy; psychosocial issues; self-management; and economic and health policy are summarized. Historic perspectives and future projections are presented. Expert commentary: The reviews establish the evidence base for the recommendations for simplification of self-management guidelines for persons at risk for and living with breast cancer-related lymphedema. Further research is needed to enhance levels of evidence for breast cancer-related lymphedema management. More rigorously-designed studies with larger samples, longer follow-up, and finely-tuned interventions and dosages are needed to extend our evidence base.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"389 - 402"},"PeriodicalIF":0.0,"publicationDate":"2016-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1230019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-02DOI: 10.1080/23809000.2016.1237262
F. Ramos, A. Fay
Quality of life of cancer patients on the wave of immunotherapy Fernanda B. Pruski Ramos & André P. Fay To cite this article: Fernanda B. Pruski Ramos & André P. Fay (2016) Quality of life of cancer patients on the wave of immunotherapy, Expert Review of Quality of Life in Cancer Care, 1:5, 351-352, DOI: 10.1080/23809000.2016.1237262 To link to this article: https://doi.org/10.1080/23809000.2016.1237262
引用本文:Fernanda B. Pruski Ramos & andr P. Fay(2016)免疫治疗浪潮下癌症患者的生活质量，癌症护理生活质量专家评论，1:5,351-352,DOI: 10.1080/23809000.2016.1237262链接到本文:https://doi.org/10.1080/23809000.2016.1237262
{"title":"Quality of life of cancer patients on the wave of immunotherapy","authors":"F. Ramos, A. Fay","doi":"10.1080/23809000.2016.1237262","DOIUrl":"https://doi.org/10.1080/23809000.2016.1237262","url":null,"abstract":"Quality of life of cancer patients on the wave of immunotherapy Fernanda B. Pruski Ramos & André P. Fay To cite this article: Fernanda B. Pruski Ramos & André P. Fay (2016) Quality of life of cancer patients on the wave of immunotherapy, Expert Review of Quality of Life in Cancer Care, 1:5, 351-352, DOI: 10.1080/23809000.2016.1237262 To link to this article: https://doi.org/10.1080/23809000.2016.1237262","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"351 - 352"},"PeriodicalIF":0.0,"publicationDate":"2016-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1237262","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-02DOI: 10.1080/23809000.2016.1236661
Jae Y. Lee, A. Abugharib, R. Nguyen, A. Eisbruch
ABSTRACT Introduction: Over the last two decades there have been dramatic intensifications in the treatment of head and neck cancer with altered fractionation or concurrent chemotherapy, both of which have been shown to improve survival at the cost of increased toxicity. Specifically, xerostomia and dysphagia negatively impact health-related quality of life (HR-QOL), and incorporation of modern radiotherapy techniques including intensity-modulated radiotherapy and volumetric arc radiotherapy have been designed to mitigate toxicity and impaired HR-QOL. Areas covered: We review the measurement of toxicity and HR-QOL, the impact of xerostomia and dysphagia on HR-QOL, and methods of preserving HR-QOL after head and neck radiotherapy. We also discuss the implications on HR-QOL of de-intensification trials for favorable-risk human papilloma virus related oropharyngeal cancer as well as a randomized trial comparing photon and proton therapy for oropharygeal cancer patients. The role of salivary stem cells and their potential impact on HR-QOL is explored. Expert commentary: With the rise of favorable-risk oropharyngeal cancer, the importance of HR-QOL in these patients has become paramount. Approaches to improve radiation-related xerostomia and dysphagia are emerging from both the physics and biological realms, but these approaches must demonstrate HR-QOL gains with sufficient rigor to justify their use in clinical practice.
{"title":"Impact of xerostomia and dysphagia on health-related quality of life for head and neck cancer patients","authors":"Jae Y. Lee, A. Abugharib, R. Nguyen, A. Eisbruch","doi":"10.1080/23809000.2016.1236661","DOIUrl":"https://doi.org/10.1080/23809000.2016.1236661","url":null,"abstract":"ABSTRACT Introduction: Over the last two decades there have been dramatic intensifications in the treatment of head and neck cancer with altered fractionation or concurrent chemotherapy, both of which have been shown to improve survival at the cost of increased toxicity. Specifically, xerostomia and dysphagia negatively impact health-related quality of life (HR-QOL), and incorporation of modern radiotherapy techniques including intensity-modulated radiotherapy and volumetric arc radiotherapy have been designed to mitigate toxicity and impaired HR-QOL. Areas covered: We review the measurement of toxicity and HR-QOL, the impact of xerostomia and dysphagia on HR-QOL, and methods of preserving HR-QOL after head and neck radiotherapy. We also discuss the implications on HR-QOL of de-intensification trials for favorable-risk human papilloma virus related oropharyngeal cancer as well as a randomized trial comparing photon and proton therapy for oropharygeal cancer patients. The role of salivary stem cells and their potential impact on HR-QOL is explored. Expert commentary: With the rise of favorable-risk oropharyngeal cancer, the importance of HR-QOL in these patients has become paramount. Approaches to improve radiation-related xerostomia and dysphagia are emerging from both the physics and biological realms, but these approaches must demonstrate HR-QOL gains with sufficient rigor to justify their use in clinical practice.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"9 1","pages":"361 - 371"},"PeriodicalIF":0.0,"publicationDate":"2016-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1236661","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-02DOI: 10.1080/23809000.2016.1236659
T. Tvedt, H. Reikvam, Elise Aasebø, M. Hernandez-Valladares, F. Berven, F. Selheim, Ø. Bruserud
ABSTRACT Introduction: Recent studies in acute myeloid leukemia (AML) suggest that self-reported health status (including quality of life) should be a part of the pretherapy evaluation especially of elderly and unfit patients. However, there is also a need for additional studies to clarify the long-term effects of various antileukemic therapies. Areas covered: We searched for original articles in the PubMed database by the following combinations of terms: (i) acute myeloid leukemia combined with quality of life, geriatric assessment, or quality of life + allogeneic stem cell transplantation; or (ii) acute myeloid leukemia combined with either elderly, unfit, low-dose cytarabine or azacitidine. Expert commentary: We review and discuss the results from studies of quality of life for AML patients treated with conventional chemotherapy, autologous and allogeneic stem cell transplantation, and patients with acute promyelocytic leukemia. Self-reported health status (including quality of life) should be a part of the pretherapy evaluation especially of elderly and unfit AML patients together with performance status, comorbidity scoring and geriatric assessment. The risk of chemoresistance to intensive treatment should also be included. All these aspects should be considered when evaluation the risk for treatment-related mortality and deciding the intensity of the antileukemic therapy.
{"title":"How should quality of life assessment be integrated in the evaluation of patients with acute myeloid leukemia?","authors":"T. Tvedt, H. Reikvam, Elise Aasebø, M. Hernandez-Valladares, F. Berven, F. Selheim, Ø. Bruserud","doi":"10.1080/23809000.2016.1236659","DOIUrl":"https://doi.org/10.1080/23809000.2016.1236659","url":null,"abstract":"ABSTRACT Introduction: Recent studies in acute myeloid leukemia (AML) suggest that self-reported health status (including quality of life) should be a part of the pretherapy evaluation especially of elderly and unfit patients. However, there is also a need for additional studies to clarify the long-term effects of various antileukemic therapies. Areas covered: We searched for original articles in the PubMed database by the following combinations of terms: (i) acute myeloid leukemia combined with quality of life, geriatric assessment, or quality of life + allogeneic stem cell transplantation; or (ii) acute myeloid leukemia combined with either elderly, unfit, low-dose cytarabine or azacitidine. Expert commentary: We review and discuss the results from studies of quality of life for AML patients treated with conventional chemotherapy, autologous and allogeneic stem cell transplantation, and patients with acute promyelocytic leukemia. Self-reported health status (including quality of life) should be a part of the pretherapy evaluation especially of elderly and unfit AML patients together with performance status, comorbidity scoring and geriatric assessment. The risk of chemoresistance to intensive treatment should also be included. All these aspects should be considered when evaluation the risk for treatment-related mortality and deciding the intensity of the antileukemic therapy.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"373 - 387"},"PeriodicalIF":0.0,"publicationDate":"2016-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1236659","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-02DOI: 10.1080/23809000.2016.1241661
D. Ehlers, L. Trinh, E. McAuley
Increasing 5-year survival rates of 69% in all cancer sites have led to over 15.5 million cancer survivors currently living in the United States [1]. Over 60% of cancer survivors are aged 65 years or older, and it is expected that older adults will comprise 70% of cancer diagnoses by 2030 [2]. Although living longer following a cancer diagnosis and treatment may appear to be a positive outcome, many cancer survivors will experience cognitive impairment which can be prevalent during active cancer therapy, remain elevated posttreatment, and impact quality of life (QoL) [3]. Cancer-related cognitive impairment (CRCI) parallels normal aging and may accelerate declines in aspects of physical condition that have established relationships with cognitive function [4]. This intersection of cancer and aging highlights the importance of studying long-term effects of cancer treatment, particularly cognitive impairment and brain health [4]. The majority of empirical research on CRCI has been in breast cancer survivors (BCS) and it is estimated that ~75% of all BCS report CRCI following treatment and the clinical prevalence of this impairment ranges from 17% to 75% [5]. Cognitive processes thought to be impaired include memory, learning, concentration, reasoning, executive function, attention, processing speed, and visual-spatial skills [5,6]. Importantly, these changes may occur both before and after treatment and have been reported up to 20 years posttreatment [5]. Evidence suggests changes in brain structure and function, hormonal changes, and neural degradation are similar among cancer patients posttreatment and healthy aging individuals [7–9]. However, the trajectory of cognitive decline after cancer treatment may occur earlier and at an accelerated rate in cancer survivors when compared with age-matched healthy adults. Given these parallel biological pathways, aging models may provide a useful platform for treating CRCI. There is strong and consistent evidence that aerobic physical activity (PA) and cardiorespiratory fitness (CRF) mitigate age-related neural degeneration and cognitive dysfunction and improve QoL in older adults [10,11]. While the physical and psychological health benefits of PA and CRF are well documented in cancer patients and survivors, the influences of PA and CRF on cognition and brain health have received limited attention in the oncology literature [12,13]. PA is increasingly being recommended as a promising behavioral approach to improve CRF and ameliorate cognitive dysfunction in cancer survivors [5,14]; however, preclinical and clinical studies are scarce [15]. Unfortunately, PA levels generally decrease after cancer diagnosis and rarely return to precancer levels after treatment ends [16,17]. One of the most important moderators of CRCI in cancer survivors may be CRF, which declines dramatically due to accelerated aging [18]. CRF has been associated with the preservation of cognitive function in older adults and increasing CRF
{"title":"The intersection of cancer and aging: implications for physical activity and cardiorespiratory fitness effects on cognition","authors":"D. Ehlers, L. Trinh, E. McAuley","doi":"10.1080/23809000.2016.1241661","DOIUrl":"https://doi.org/10.1080/23809000.2016.1241661","url":null,"abstract":"Increasing 5-year survival rates of 69% in all cancer sites have led to over 15.5 million cancer survivors currently living in the United States [1]. Over 60% of cancer survivors are aged 65 years or older, and it is expected that older adults will comprise 70% of cancer diagnoses by 2030 [2]. Although living longer following a cancer diagnosis and treatment may appear to be a positive outcome, many cancer survivors will experience cognitive impairment which can be prevalent during active cancer therapy, remain elevated posttreatment, and impact quality of life (QoL) [3]. Cancer-related cognitive impairment (CRCI) parallels normal aging and may accelerate declines in aspects of physical condition that have established relationships with cognitive function [4]. This intersection of cancer and aging highlights the importance of studying long-term effects of cancer treatment, particularly cognitive impairment and brain health [4]. The majority of empirical research on CRCI has been in breast cancer survivors (BCS) and it is estimated that ~75% of all BCS report CRCI following treatment and the clinical prevalence of this impairment ranges from 17% to 75% [5]. Cognitive processes thought to be impaired include memory, learning, concentration, reasoning, executive function, attention, processing speed, and visual-spatial skills [5,6]. Importantly, these changes may occur both before and after treatment and have been reported up to 20 years posttreatment [5]. Evidence suggests changes in brain structure and function, hormonal changes, and neural degradation are similar among cancer patients posttreatment and healthy aging individuals [7–9]. However, the trajectory of cognitive decline after cancer treatment may occur earlier and at an accelerated rate in cancer survivors when compared with age-matched healthy adults. Given these parallel biological pathways, aging models may provide a useful platform for treating CRCI. There is strong and consistent evidence that aerobic physical activity (PA) and cardiorespiratory fitness (CRF) mitigate age-related neural degeneration and cognitive dysfunction and improve QoL in older adults [10,11]. While the physical and psychological health benefits of PA and CRF are well documented in cancer patients and survivors, the influences of PA and CRF on cognition and brain health have received limited attention in the oncology literature [12,13]. PA is increasingly being recommended as a promising behavioral approach to improve CRF and ameliorate cognitive dysfunction in cancer survivors [5,14]; however, preclinical and clinical studies are scarce [15]. Unfortunately, PA levels generally decrease after cancer diagnosis and rarely return to precancer levels after treatment ends [16,17]. One of the most important moderators of CRCI in cancer survivors may be CRF, which declines dramatically due to accelerated aging [18]. CRF has been associated with the preservation of cognitive function in older adults and increasing CRF ","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"347 - 350"},"PeriodicalIF":0.0,"publicationDate":"2016-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1241661","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-02DOI: 10.1080/23809000.2016.1236660
A. Dahl, Rasmus Nilsson, K. Axcrona, S. Fosså
ABSTRACT Introduction: Erectile dysfunction is a common and severe adverse effect after radical prostatectomy for prostate cancer. Research on post-surgical erectile dysfunction has so far mostly focused on physiology, prevalence, related factors, and treatment. This review takes a broader approach adding an integrated theory of sexuality as well as social, relational, and psychological perspectives. Areas covered: In this updated review, we have incorporated recent data concerning erectile dysfunction after radical prostatectomy regarding theories of sexuality and masculinity, relevant aspects of sexual function, management of erectile dysfunction, psychological reactions to and interventions toward erectile dysfunction in men treated for prostate cancer, and finally social attitudes towards sex in elderly people. Expert commentary: The physiological and patient-only approach to erectile dysfunction after radical prostatectomy has definite limitations. In the future this problem must be approached in a broader perspective in order to reach optimal sexual life for the patients and their partners.
{"title":"Addressing erectile dysfunction in prostate cancer survivors after radical prostatectomy","authors":"A. Dahl, Rasmus Nilsson, K. Axcrona, S. Fosså","doi":"10.1080/23809000.2016.1236660","DOIUrl":"https://doi.org/10.1080/23809000.2016.1236660","url":null,"abstract":"ABSTRACT Introduction: Erectile dysfunction is a common and severe adverse effect after radical prostatectomy for prostate cancer. Research on post-surgical erectile dysfunction has so far mostly focused on physiology, prevalence, related factors, and treatment. This review takes a broader approach adding an integrated theory of sexuality as well as social, relational, and psychological perspectives. Areas covered: In this updated review, we have incorporated recent data concerning erectile dysfunction after radical prostatectomy regarding theories of sexuality and masculinity, relevant aspects of sexual function, management of erectile dysfunction, psychological reactions to and interventions toward erectile dysfunction in men treated for prostate cancer, and finally social attitudes towards sex in elderly people. Expert commentary: The physiological and patient-only approach to erectile dysfunction after radical prostatectomy has definite limitations. In the future this problem must be approached in a broader perspective in order to reach optimal sexual life for the patients and their partners.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"1 1","pages":"403 - 420"},"PeriodicalIF":0.0,"publicationDate":"2016-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1236660","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-08-04DOI: 10.1080/23809000.2016.1214058
O. Kirkizlar, A. E. Eşkazan
ABSTRACT Introduction: Since the life expectancy of chronic phase chronic myeloid leukemia (CML) patients increased in the era of the tyrosine kinase inhibitors (TKIs), both the CML caring physicians and the patients face another important issue – quality of life (QoL). In daily clinical practice, in order to improve QoL, managing adverse events (AEs) of the TKIs and maintaining the patients’ adherence to the TKI treatment are becoming really important. Areas covered: This review mainly focuses on the AEs of TKIs and their impact on the QoL among patients with CML. Expert commentary: The evaluation of QoL in patients with CML receiving TKIs with different scales as well as patient reported outcomes (PROs) will help physicians to proactively address issues related to QoL and the proper management of these AEs will help patients to live a near-normal life.
{"title":"Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia","authors":"O. Kirkizlar, A. E. Eşkazan","doi":"10.1080/23809000.2016.1214058","DOIUrl":"https://doi.org/10.1080/23809000.2016.1214058","url":null,"abstract":"ABSTRACT Introduction: Since the life expectancy of chronic phase chronic myeloid leukemia (CML) patients increased in the era of the tyrosine kinase inhibitors (TKIs), both the CML caring physicians and the patients face another important issue – quality of life (QoL). In daily clinical practice, in order to improve QoL, managing adverse events (AEs) of the TKIs and maintaining the patients’ adherence to the TKI treatment are becoming really important. Areas covered: This review mainly focuses on the AEs of TKIs and their impact on the QoL among patients with CML. Expert commentary: The evaluation of QoL in patients with CML receiving TKIs with different scales as well as patient reported outcomes (PROs) will help physicians to proactively address issues related to QoL and the proper management of these AEs will help patients to live a near-normal life.","PeriodicalId":91681,"journal":{"name":"Expert review of quality of life in cancer care","volume":"43 1","pages":"353 - 359"},"PeriodicalIF":0.0,"publicationDate":"2016-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23809000.2016.1214058","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60122774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：